Target intelligence / Profile preview

SARS-CoV-2 3-chymotrypsin-like protease, papain-like protease, and helicase (3CLpro, PLpro, and nsp13)

Target
3CLpro, PLpro, and nsp13
Molecular classification
Enzyme, Protease, Cysteine protease, Helicase, Hydrolase
01

Overview

The target complex described refers to three critical enzymes of the SARS-CoV-2 virus: the 3-chymotrypsin-like protease (3CLpro or Mpro), the papain-like protease (PLpro), and the helicase (nsp13). 3CLpro (nsp5) and PLpro (a domain of nsp3) are essential for the proteolytic processing of the viral polyproteins pp1a and pp1ab into functional non-structural proteins required for the viral replication-transcription complex (UniProt P0DTD1; PubMed: 32404437). PLpro additionally facilitates immune evasion by cleaving ubiquitin and ISG15 from host proteins, thereby antagonizing the innate immune response (PubMed: 32726803). The helicase (nsp13) is a highly conserved enzyme that unwinds double-stranded RNA in an ATP-dependent manner, a process vital for viral genome replication (PubMed: 32807195). Quercetin, a natural flavonoid, has been identified through in silico and in vitro studies as a potential multi-target inhibitor capable of binding to the active sites of these enzymes, particularly 3CLpro, to disrupt viral activity (PubMed: 33034336). This entry is marked as incorrect because it combines three distinct viral targets and a specific ligand (quercetin) into a single target designation.

Other names
Main proteaseMpronsp5Papain-like proteasensp3nsp13Non-structural protein 5Non-structural protein 3Non-structural protein 13SARS-CoV-2 3CLproSARS-CoV-2 PLproSARS-CoV-2 helicase
02

Mechanism of action

Quercetin acts as a multi-target inhibitor that binds to the active sites or allosteric pockets of 3CLpro, PLpro, and the helicase (nsp13), thereby inhibiting viral polyprotein processing and RNA replication.

03

Biological functions

Viral replicationPolyprotein processingRNA unwindingImmune evasionProteolysis
04

Disease associations

InfectionCOVID-19
05

Safety considerations

Low oral bioavailability of quercetinPotential for cytochrome P450 drug-drug interactionsRisk of viral resistance mutations in protease genesLack of clinical efficacy data for quercetin as a primary antiviral
06

Interacting drugs

Quercetin

3 more in the full profile.

07

Biomarkers

SARS-CoV-2 viral loadC-reactive proteinD-dimerInterleukin-6

Beyond the preview

Go deeper on SARS-CoV-2 3-chymotrypsin-like protease, papain-like protease, and helicase (3CLpro, PLpro, and nsp13).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 3-chymotrypsin-like protease, papain-like protease, and helicase (3CLpro, PLpro, and nsp13).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call